Claims for Patent: 11,267,799

Summary for Patent: 11,267,799

Title:	Solid forms of an HIV capsid inhibitor
Abstract:	The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
Inventor(s):	Bing Shi
Assignee:	Gilead Sciences Inc
Application Number:	US15/998,786
Patent Claims:	1. A crystalline form of N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide sodium salt, which is crystalline Form I. 2. The crystalline form of claim 1, wherein the crystalline Form I has at least three XRPD peaks, in terms of 2-theta±0.2°, selected from 5.6°, 6.6°, 10.9°, 13.4°, 16.8°, 17.1°, 21.8°, 24.1°, and 26.9°. 3. The crystalline form of claim 1, wherein the crystalline Form I is characterized by an XRPD pattern substantially as shown in FIG. 1. 4. The crystalline form of claim 1, wherein the crystalline Form I is characterized by a DSC thermogram having a melting onset of about 218° C. 5. The crystalline form of claim 1, wherein the crystalline Form I is characterized by a DSC thermogram substantially as shown in FIG. 2. 6. A crystalline form of N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide sodium salt, which is crystalline Form II. 7. The crystalline form of claim 6, wherein the crystalline Form II has at least three XRPD peaks, in terms of 2-theta±0.2°, selected from 5.4°, 7.0°, 11.1°, 17.7°, 19.2°, 21.2°, 22.6°, 24.0°, and 27.7°. 8. The crystalline form of claim 6, wherein the crystalline Form II is characterized by an XRPD pattern substantially as shown in FIG. 3. 9. The crystalline form of claim 6, wherein the crystalline Form II is characterized by a DSC thermogram having a melting onset of about 222° C. 10. The crystalline form of claim 6, wherein the crystalline Form II is characterized by a DSC thermogram substantially as shown in FIG. 4. 11. A crystalline form of N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide sodium salt, which is crystalline Form III. 12. The crystalline form of claim 11, wherein the crystalline Form III has at least three XRPD peaks, in terms of 2-theta±0.2°, selected from 5.9°, 7.1°, 11.6°, 15.4°, 17.2°, 18.4°, 19.5°, 22.2°, and 27.2°. 13. The crystalline form of claim 11, wherein the crystalline Form III is characterized by an XRPD pattern substantially as shown in FIG. 5. 14. The crystalline form of claim 11, wherein the crystalline Form III is characterized by a DSC thermogram having a melting onset of about 213° C. 15. The crystalline form of claim 11, wherein the crystalline Form III is characterized by a DSC thermogram substantially as shown in FIG. 6. 16. A pharmaceutical composition comprising the crystalline form of claim 1, and at least one pharmaceutically acceptable excipient. 17. A pharmaceutical composition comprising the crystalline form of claim 6, and at least one pharmaceutically acceptable excipient. 18. A pharmaceutical composition comprising the crystalline form of claim 11, and at least one pharmaceutically acceptable excipient. 19. A method of treating or preventing a human immunodeficiency virus (HIV) infection comprising administering a therapeutically effective amount of the crystalline form of claim 3 to a subject in need thereof. 20. The method of claim 19, wherein the method comprises administering the crystalline form in combination with one, two, three, or four additional therapeutic agents.